Steffen Walter

Chief Operating Officer at IMMATICS N.V.

Net worth: 3 M $ as of 2024-03-30

47 year

Health Technology

Consumer Services

Profile

Steffen Walter founded Immatics US, Inc. in 2015, where he is working as Chief Scientific Officer from 2015.
Dr. Walter also currently works at Immatics Biotechnologies GmbH, as Chief Technology Officer from 2020 and Immatics NV, as Chief Operations Officer from 2023.
Dr. Walter received his doctorate degree from Eberhard Karls Universität Tübingen.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
IMMATICS N.V. 0.27%	2024-01-30	279,892 ( 0.27% )	3 M $	2024-03-30

Steffen Walter active positions

Companies	Position	Start
IMMATICS N.V.	Chief Operating Officer	2023-03-20
Immatics US, Inc. Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.	Founder	2014-12-31
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Chief Tech/Sci/R&D Officer	2004-12-31

All active positions of Steffen Walter

Training of Steffen Walter

Eberhard Karls Universität Tübingen

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Steffen Walter's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
IMMATICS N.V.	Health Technology

Private companies	2
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Health Technology
Immatics US, Inc. Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.	Health Technology